

Richard F Schlenk

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4932375/richard-f-schlenk-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

316
papers

16,798
citations

53
h-index

128
g-index

320
ext. papers

19,812
ext. citations

4.8
avg, IF

6.03
L-index

#	Paper	IF	Citations
316	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.. <i>Nature Cancer</i> , 2022 , 3, 251-261	15.4	3
315	Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease. <i>Blood</i> , 2021 , 138, 3404-3404	2.2	
314	Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4. <i>Blood</i> , 2021 , 138, 1307-1307	2.2	
313	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. <i>Blood</i> , 2021 , 138, 692-692	2.2	0
312	Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status. <i>Blood</i> , 2021 , 138, 2380-2380	2.2	0
311	Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition. <i>Blood</i> , 2021 , 138, 3469-3469		
310	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. <i>Blood</i> , 2021 , 138, 4418-4418 ⁰	2.2	0
309	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551	10.7	15
308	Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). <i>Annals of Hematology</i> , 2021 , 100, 1463-1471	3	
307	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with -mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. <i>Haematologica</i> , 2021 , 106, 2986-2989	6.6	1
306	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study. <i>Haematologica</i> , 2021 , 106, 3100-3106	6.6	6
305	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021 , 11, 2780-2795	24.4	24
304	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021 , 137, 3093-3104	2.2	19
303	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). <i>Journal of Clinical Oncology</i> , 2021 , 39, 3318-3327	2.2	7
302	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021 , 35, 701-711	10.7	21
301	Ruxolitinib is effective in the treatment of a patient with refractory T-ALL. <i>EJHaem</i> , 2021 , 2, 139-142	0.9	
300	Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. <i>Oncologist</i> , 2021 , 26, 7-16	5.7	14

299	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. <i>British Journal of Haematology</i> , 2021 , 192, 832-842	4.5	4
298	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021 , 5, 4370-4379	7.8	1
297	Requirement for LIM kinases in acute myeloid leukemia. <i>Leukemia</i> , 2020 , 34, 3173-3185	10.7	5
296	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020 , 26, 992-994	50.5	19
295	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. <i>Leukemia</i> , 2020 , 34, 2333-2341	10.7	13
294	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020 , 105, 2440-2447	6.6	14
293	Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls. <i>Biometrical Journal</i> , 2020 , 62, 311-329	1.5	2
292	Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 623-632	2.2	35
291	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. <i>Leukemia</i> , 2020 , 34, 1182-1186	10.7	24
290	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
289	Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. <i>BMJ Open</i> , 2020 , 10, e039639	3	4
288	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020 , 136, 3041-3050	2.2	30
287	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , 2020 , 4, 6342-6352	7.8	11
286	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020 , 105, 161-169	6.6	8
285	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020 , 34, 914-918	10.7	26
284	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53
283	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019 , 134, 1608-1618	2.2	45
282	Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019 , 184, 1018-1021	4.5	16

281	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2019 , 85, 106197	2.7	8
280	Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. <i>Blood</i> , 2019 , 134, 2693-2693	2.2	1
279	Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease. <i>Blood</i> , 2019 , 134, 3928-3928	2.2	3
278	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG). <i>Blood</i> , 2019 , 134, 2740-2740	2.2	
277	Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network. <i>Blood</i> , 2019 , 134, 2998-2998	2.2	3
276	Community-driven development of a modified progression-free survival ratio for precision oncology. <i>ESMO Open</i> , 2019 , 4, e000583	6	9
275	Whats new in consolidation therapy in AML?. <i>Seminars in Hematology</i> , 2019 , 56, 96-101	4	8
274	Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. <i>Haematologica</i> , 2019 , 104, e63-e64	6.6	4
273	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. <i>Blood</i> , 2019 , 133, 840-851	2.2	141
272	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019 , 185, 583-587	4.5	5
271	Targeting FLT3 mutations in AML: review of current knowledge and evidence. <i>Leukemia</i> , 2019 , 33, 299-310.7	310.7	324
270	Acute myelogenous leukemia in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27089	270.89	29
269	A new option for remission induction in acute myeloid leukaemia. <i>Lancet Oncology, The</i> , 2018 , 19, 156-157.7	157.7	3
268	Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. <i>Haematologica</i> , 2018 , 103, e25-e28	6.6	14
267	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. <i>Leukemia</i> , 2018 , 32, 1621-1630	10.7	53
266	Management of patients with acute promyelocytic leukemia. <i>Leukemia</i> , 2018 , 32, 1277-1294	10.7	50
265	Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial. <i>Blood</i> , 2018 , 132, 4045-4045	2.2	12
264	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. <i>Blood</i> , 2018 , 132, 1501-1501	2.2	3

263	Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study). <i>Blood</i> , 2018 , 132, 208-208	2.2	12
262	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. <i>Blood</i> , 2018 , 132, 720-720	2.2	4
261	A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. <i>Journal of Medical Internet Research</i> , 2018 , 20, e10976	7.6	11
260	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide In An International Collaborative Study. <i>Blood</i> , 2018 , 132, 80-80	2.2	
259	The Genes for Tissue Factor F3 and Nuclear Receptor 4A Are Down-Regulated in Early Death Acute Promyelocytic Leukemia Patients. <i>Blood</i> , 2018 , 132, 3902-3902	2.2	
258	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AML5G 17-10 CIARA trial). <i>British Journal of Haematology</i> , 2018 , 183, 235-241	4.5	2
257	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017 , 49, 332-340	36.3	155
256	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 454-464	59.2	1067
255	Precision oncology based on omics data: The NCT Heidelberg experience. <i>International Journal of Cancer</i> , 2017 , 141, 877-886	7.5	82
254	Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. <i>Journal of Medical Genetics</i> , 2017 , 54, 640-650	5.8	
253	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. <i>Annals of Hematology</i> , 2017 , 96, 887-894	3	3
252	Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1177-1189	3.8	15
251	Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 2039-2047	6.6	51
250	Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. <i>Leukemia Research</i> , 2017 , 62, 84-90	2.7	5
249	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2017 , 99, 544-552	3.8	4
248	Relapsed/refractory acute myeloid leukemia: any progress?. <i>Current Opinion in Oncology</i> , 2017 , 29, 467-473	4.7	28
247	Analysis of splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. <i>Oncotarget</i> , 2017 , 8, 95163-95175	3.3	6
246	Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2056-2056	2.2	256

245	Is there justification for 4 cycles of consolidation therapy in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 341-344	4.2	7
244	MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses. <i>Haematologica</i> , 2016 , 101, e454-e456	6.6	5
243	The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016 , 48, 1551-1556	16.5	147
242	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 2209-2221	59.2	1999
241	Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. <i>Epigenetics</i> , 2016 , 11, 517-25	5.7	18
240	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016 , 128, 112-112	2.2	2
239	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG). <i>Blood</i> , 2016 , 128, 1207-1207	2.2	9
238	CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial. <i>Blood</i> , 2016 , 128, 1608-1608	2.2	9
237	Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110). <i>Blood</i> , 2016 , 128, 1939-1939	2.2	5
236	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 337-337	2.2	1
235	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2016 , 128, 4271-4271	2.2	4
234	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. <i>Blood</i> , 2016 , 128, 449-449	2.2	15
233	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016 , 128, 479-479	2.2	20
232	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , 2016 , 128, 589-589	2.2	11
231	Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling. <i>PLoS ONE</i> , 2016 , 11, e0155226	3.7	5
230	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. <i>Oncotarget</i> , 2016 , 7, 49539-49551	3.3	10
229	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA). <i>Blood</i> , 2016 , 128, 4038-4038	2.2	
228	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. <i>Blood</i> , 2016 , 128, 2815-2815	2.2	1

227	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. <i>Haematologica</i> , 2016 , 101, 839-45	6.6	19
226	Targeted Therapy Alone for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 1197-8	59.2	45
225	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , 2016 , 95, 1931-1942	3.9	52
224	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , 2015 , 126, 319-27	2.2	185
223	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. <i>British Journal of Haematology</i> , 2015 , 169, 694-700	4.5	71
222	Minimal residual disease-directed therapy in acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2331-5	2.2	33
221	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e122-4	6.6	12
220	Minimal residual disease in acute myeloid leukemia--current status and future perspectives. <i>Current Hematologic Malignancy Reports</i> , 2015 , 10, 132-44	4.4	24
219	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , 2015 , 100, 324-30	6.6	67
218	Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 1381-1381	2.2	1
217	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2015 , 126, 1669-1669	2.2	14
216	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015 , 126, 226-226	2.2	3
215	Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3-ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015 , 126, 2585-2585	2.2	1
214	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 2586-2586	2.2	1
213	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. <i>Blood</i> , 2015 , 126, 2891-2891	2.2	1
212	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , 2015 , 126, 322-322	2.2	30
211	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 3744-3744	2.2	7
210	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2015 , 126, 3818-3818	2.2	0

209	Long-Term Interferon- α Treatment in Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 4064-4064	2.2	4
208	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)	2.2	93
207	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015 , 126, 609-609	2.2	5
206	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. <i>Blood</i> , 2015 , 126, 803-803	2.2	2
205	A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis. <i>Blood</i> , 2015 , 126, 826-826	2.2	8
204	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. <i>Blood</i> , 2015 , 126, 85-85	2.2	1
203	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2553-2553	2.2	
202	Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome. <i>Blood</i> , 2015 , 126, 4123-4123	2.2	
201	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. <i>Blood</i> , 2015 , 126, 224-224	2.2	
200	Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 3844-3844	2.2	
199	Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome. <i>Blood</i> , 2015 , 126, 5523-5523	2.2	
198	Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015 , 126, 227-227	2.2	
197	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. <i>Blood</i> , 2014 , 123, 914-20	2.2	129
196	Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3406-12	2.2	61
195	Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. <i>Haematologica</i> , 2014 , 99, e133-5	6.6	10
194	Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. <i>Blood</i> , 2014 , 123, 4027-36	2.2	60
193	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. <i>Blood</i> , 2014 , 124, 1426-33	2.2	172
192	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2114-9	1.9	11

191	Gemtuzumab ozogamicin in acute myeloid leukemia revisited. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1185-95	5.4	37
190	Post-remission therapy for acute myeloid leukemia. <i>Haematologica</i> , 2014 , 99, 1663-70	6.6	69
189	Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. <i>Leukemia Research</i> , 2014 , 38, 57-64	2.7	50
188	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia [Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , 2014 , 124, 12-12	2.2	5
187	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). <i>Blood</i> , 2014 , 124, 1992-1992	2.2	2
186	A Multicenter Phase-Ib/II Study of Ruxolitinib/Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis: Safety Data from the Mpmsg-0212 Trial (NCT01644110). <i>Blood</i> , 2014 , 124, 3161-3161	2.2	1
185	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , 2014 , 124, 1254-1254	2.2	
184	ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance?. <i>Blood</i> , 2014 , 124, 3618-3618	2.2	
183	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts . <i>Blood</i> , 2014 , 124, 2636-2636	2.2	
182	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG and the European LeukemiaNet (ELN). <i>Blood</i> , 2014 , 124, 231-231	2.2	
181	A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial. <i>Blood</i> , 2014 , 124, 1918-1918	2.2	
180	NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 2338-2338	2.2	
179	Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial. <i>Blood</i> , 2014 , 124, 1920-1920	2.2	
178	Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>New England Journal of Medicine</i> , 2013 , 369, 111-21	59.2	964
177	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , 2013 , 121, 4769-77	2.2	129
176	Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. <i>Leukemia Research</i> , 2013 , 37, 900-6	2.7	17
175	PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17). <i>Clinical Cancer Research</i> , 2013 , 19, 2562-71	12.9	29
174	Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2013 , 121, 170-7	2.2	134

173	The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. <i>Blood</i> , 2013 , 122, 1576-82	2.2	115
172	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In	2.2	3
171	Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response □ Evolutionary -, and Remission Patterns and No Increased Karyotype Evolution (KE). <i>Blood</i> , 2013 , 122, 2783-2783	2.2	2
170	Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013 , 122, 3756-3756	2.2	4
169	Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study. <i>Blood</i> , 2013 , 122, 4064-4064	2.2	1
168	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013 , 122, 527-527	2.2	7
167	The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2563-2563	2.2	
166	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. <i>Blood</i> , 2013 , 122, 2555-2555	2.2	
165	Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 830-830	2.2	
164	Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , 2013 , 122, 3878-3878	2.2	
163	Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013 , 122, 2539-2539	2.2	2
162	An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1. <i>Blood</i> , 2013 , 122, 2593-2593	2.2	
161	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2013 , 122, 1332-1332	2.2	
160	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1314-1314	2.2	
159	Pomalidomide In MPN-associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study. <i>Blood</i> , 2013 , 122, 2822-2822	2.2	
158	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. <i>Blood</i> , 2013 , 122, 2759-2759	2.2	2
157	Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study. <i>Blood</i> , 2013 , 122, 3927-3927	2.2	
156	Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. <i>Blood</i> , 2012 , 119, 551-8	2.2	120

155	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012 , 119, e67-75	2.2	59
154	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 579-90	19.4	303
153	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. <i>Blood</i> , 2012 , 120, e83-92	2.2	110
152	Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). <i>Annals of Hematology</i> , 2012 , 91, 1519-31	3	29
151	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood</i> , 2012 , 119, 2114-21	2.2	411
150	TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1350-7	2.2	166
149	Therapy-related myeloid neoplasms following treatment with radioiodine. <i>Haematologica</i> , 2012 , 97, 206-12	6.6	32
148	Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653). <i>Blood</i> , 2012 , 120, 1483-1483	2.2	4
147	CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study. <i>Blood</i> , 2012 , 120, 3816-3816	2.2	2
146	Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322). <i>Blood</i> , 2012 , 120, 412-412	2.2	1
145	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. <i>Blood</i> , 2012 , 120, 6-6	2.2	12
144	Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. <i>Blood</i> , 2012 , 120, 3801-3801	2.2	
143	Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems. <i>Blood</i> , 2012 , 120, 734-734	2.2	
142	Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 0109 Study (ClinicalTrials.gov Identifier: NCT00949364).. <i>Blood</i> , 2012 , 120, 2840-2840	2.2	
141	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. <i>Blood</i> , 2012 , 120, 46-46	2.2	
140	Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. <i>Blood</i> , 2012 , 120, 785-785	2.2	
139	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <i>Blood</i> , 2011 , 117, 2469-75	2.2	276
138	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. <i>Haematologica</i> , 2011 , 96, 1783-91	6.6	36

137	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , 2011 , 117, 2137-45	2.2	306
136	Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 51-8	5	6
135	RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1364-72	2.2	245
134	Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 1369-80	5.4	7
133	Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2709-16	2.2	297
132	Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 682-9	2.2	47
131	Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML. <i>Blood</i> , 2011 , 118, 1549-1549	2.2	6
130	TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome. <i>Blood</i> , 2011 , 118, 3558-3558	2.2	3
129	ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG. <i>Blood</i> , 2011 , 118, 412-412	2.2	1
128	DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. <i>Blood</i> , 2011 , 118, 415-415	2.2	1
127	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 423-423	2.2	2
126	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia [Results of the AMLSG 07-04 Randomized Treatment Trial. <i>Blood</i> , 2011 , 118, 80-80	2.2	12
125	Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. <i>Cancer Management and Research</i> , 2011 , 3, 157-75	3.6	3
124	Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples. <i>Blood</i> , 2011 , 118, 237-237	2.2	
123	Integrative Genomics Approaches Identify Novel Disease-Related Genetic Aberrations in Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 402-402	2.2	
122	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. <i>Blood</i> , 2011 , 118, 1533-1533	2.2	
121	Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations. <i>Blood</i> , 2011 , 118, 3546-3546	2.2	
120	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. <i>Blood</i> , 2011 , 118, 1441-1441	2.2	

119	KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. <i>British Journal of Haematology</i> , 2010 , 148, 925-37	4.5	36
118	Prognostic impact of minimal residual disease in CBFβ-MYH11-positive acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3724-9	2.2	110
117	High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2101-7	2.2	189
116	Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4642-8	2.2	178
115	Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3890-8	2.2	167
114	Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. <i>Blood</i> , 2010 , 115, 636-42	2	121
113	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 726-32	5	29
112	A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML. <i>Blood</i> , 2010 , 116, 3285-3285	2.2	2
111	Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine. <i>Blood</i> , 2010 , 116, 3316-3316	2.2	10
110	Mutations of EZH2 In Myeloproliferative Neoplasms with Myelofibrosis: Correlation with Molecular and Clinical Data. <i>Blood</i> , 2010 , 116, 4111-4111	2.2	1
109	Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications. <i>Blood</i> , 2010 , 116, 909-909	2.2	6
108	TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2010 , 116, 97-97	2.2	5
107	Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study. <i>Blood</i> , 2010 , 116, 185-185	2.2	
106	AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms. <i>Blood</i> , 2010 , 116, 291-291	2.2	1
105	Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. <i>Blood</i> , 2010 , 116, 2184-2184	2.2	
104	A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010 , 116, 3310-3310	2.2	
103	Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG). <i>Blood</i> , 2010 , 116, 101-101	2.2	
102	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. <i>Blood</i> , 2010 , 116, 849-849	2.2	

101	Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup. <i>Blood</i> , 2010 , 116, 2175-2175	2.2	
100	NF1 Alterations Are Common In AML with Complex Karyotype and Correlate with Specific Genomic Imbalances. <i>Blood</i> , 2010 , 116, 4179-4179	2.2	0
99	Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 3297-3297	2.2	
98	Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification. <i>Blood</i> , 2010 , 116, 1693-1693	2.2	
97	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 2349-61	27.4	612
96	Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3994-4001	2.2	230
95	Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2009 , 16, 98-104	3.3	44
94	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. <i>Haematologica</i> , 2009 , 94, 54-60	6.6	164
93	Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG.. <i>Blood</i> , 2009 , 114, 1600-1600	2.2	1
92	In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.. <i>Blood</i> , 2009 , 114, 2632-2632	2.2	2
91	Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).. <i>Blood</i> , 2009 , 114, 824-824	2.2	2
90	Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).. <i>Blood</i> , 2009 , 114, 945-945	2.2	4
89	Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. <i>Blood</i> , 2009 , 114, 578-578	2.2	
88	High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.. <i>Blood</i> , 2009 , 114, 582-582	2.2	
87	Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. <i>Blood</i> 2009 , 114, 2621-2621	2.2	
86	Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).. <i>Blood</i> , 2009 , 114, 825-825	2.2	1
85	Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).. <i>Blood</i> , 2009 , 114, 1586-1586	2.2	
84	Deregulated Apoptotic Pathways Point to Effectiveness of IAP Inhibitor Therapy in Acute Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 1275-1275	2.2	

83	Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 2391-2391	2.2	
82	Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML.. <i>Blood</i> , 2009 , 114, 2613-2613	2.2	
81	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2008 , 358, 1909-18	59.2	1330
80	HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 187-96	4.7	41
79	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , 2008 , 93, 1219-26	6.6	20
78	Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 826-33	6.6	57
77	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. <i>Blood</i> , 2008 , 111, 1357-65	2.2	170
76	An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. <i>Blood</i> , 2008 , 111, 4490-5	2.2	83
75	Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid. <i>Haematologica</i> , 2008 , 93, 1105-7	6.6	4
74	RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG). <i>Blood</i> , 2008 , 112, 145-145	2.2	1
73	Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy.. <i>Blood</i> , 2008 , 112, 1953-1953	2.2	2
72	Role of Etoposide in Combination with All-Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation. <i>Blood</i> , 2008 , 112, 559-559	2.2	2
71	Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1. <i>Blood</i> , 2008 , 112, 2514-2514	2.2	
70	Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.. <i>Blood</i> , 2008 , 112, 1487-1487	2.2	
69	Distinct Expression Patterns in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Characterized by Uniparental Disomy.. <i>Blood</i> , 2008 , 112, 1193-1193	2.2	
68	Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG). <i>Blood</i> , 2008 , 112, 699-699	2.2	
67	Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients. <i>Blood</i> , 2008 , 112, 2641-2641	2.2	1
66	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. <i>Blood</i> , 2008 , 112, 2973-2973	2.2	1

65	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <i>Haematologica</i> , 2007 , 92, 763-70	6.6	39
64	Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials. <i>Oncology Research and Treatment</i> , 2007 , 30, 657-62	2.8	8
63	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1037-48	15.9	100
62	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. <i>Blood</i> , 2007 , 110, 1806-1806	2.2	1
61	The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.. <i>Blood</i> , 2007 , 110, 297-297	2.2	7
60	CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.. <i>Blood</i> , 2007 , 110, 363-363	2.2	1
59	Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).. <i>Blood</i> , 2007 , 110, 364-364	2.2	2
58	Combined Analysis of Valproic Acid Induced MicroRNA and Gene Expression Changes in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 869-869	2.2	1
57	Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 3485-3485	2.2	
56	Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 1446-1446	2.2	
55	Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial.. <i>Blood</i> , 2007 , 110, 1836-1836	2.2	
54	Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).. <i>Blood</i> , 2007 , 110, 762-762	2.2	
53	KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.. <i>Blood</i> , 2007 , 110, 3163-3163	2.2	
52	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.. <i>Blood</i> , 2007 , 110, 1837-1837	2.2	
51	The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.. <i>Blood</i> , 2007 , 110, 881-881	2.2	
50	Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.. <i>Blood</i> , 2007 , 110, 759-759 ^{2.2}	2.2	1
49	The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. <i>Cancer</i> , 2006 , 106, 112-9	6.4	197
48	Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2006 , 24, 969-75	2.2	157

47	Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3887-94	2.2	127
46	Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. <i>Blood</i> , 2006 , 107, 1242-32.	2.2	55
45	Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. <i>Blood</i> , 2006 , 108, 3280-8	2.2	234
44	Risk-Adapted Therapy in Younger Adults with Acute Myeloid Leukemia: Results of the AMLHD98A Trial of the AMLSG.. <i>Blood</i> , 2006 , 108, 14-14	2.2	21
43	Characterization of NPM1-Mutated/FLT3 ITD-Negative Acute Myeloid Leukemia with Normal Karyotype by Gene Expression Profiling.. <i>Blood</i> , 2006 , 108, 155-155	2.2	1
42	Prognosis of Adult Patients \geq 60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.. <i>Blood</i> , 2006 , 108, 16-16	2.2	2
41	Impact of Pegfilgrastim on Hematological Reconstitution and Incidence of Neutropenic Fever after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukemia: Comparative Analysis between AMLSG 07-04 and the German AML Intergroup Trial.. <i>Blood</i> , 2006 , 108, 2020-2020	2.2	2
40	Gene Mutations as Predictive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.. <i>Blood</i> , 2006 , 108, 4-4	2.2	10
39	A FLT3 Gene-Expression Signature Outperforms FLT3 Status in Predicting Clinical Outcome for Patients with Normal Karyotype AML.. <i>Blood</i> , 2006 , 108, 2311-2311	2.2	
38	Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.. <i>Blood</i> , 2006 , 108, 2301-2301	2.2	1
37	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. <i>Blood</i> , 2006 , 108, 1949-1949	2.2	
36	Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 8-8	2.2	2
35	Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.. <i>Blood</i> , 2006 , 108, 414-414	2.2	
34	In Vitro and In Vivo Monitoring of Valproic Acid Effects on Gene Expression Signatures in Adult Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 2605-2605	2.2	
33	RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.. <i>Blood</i> , 2006 , 108, 2303-2303	2.2	1
32	Minimal Residual Disease (MRD) Monitoring in CBFM-MYH11 Acute Myeloid Leukemia (AML) Is of Prognostic Relevance for Relapse-Free Survival.. <i>Blood</i> , 2006 , 108, 2298-2298	2.2	
31	Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 278-86	8.9	16
30	Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. <i>Haematologica</i> , 2006 , 91, 285-6	6.6	15

29	JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. <i>Haematologica</i> , 2006 , 91, 1569-70	6.6	18
28	Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 427-32	5	33
27	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.. <i>Blood</i> , 2005 , 106, 1852-1852	2.2	12
26	Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3-ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.. <i>Blood</i> , 2005 , 106, 2353-2353	2.2	2
25	Prognosis of Adult Patients \geq 60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups.. <i>Blood</i> , 2005 , 106, 2360-2360	2.2	2
24	Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.. <i>Blood</i> , 2005 , 106, 2800-2800	2.2	2
23	Pooled Data Analysis of Acute Myeloid Leukemia Patients \leq 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.. <i>Blood</i> , 2005 , 106, 2374-2374	2.2	
22	Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.. <i>Blood</i> , 2005 , 106, 2474-2474	2.2	
21	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. <i>Blood</i> , 2005 , 106, 1849-1849	2.2	
20	Prognostic Gene-Expression Signatures in Adult Acute Myeloid Leukemia with Normal Karyotype.. <i>Blood</i> , 2005 , 106, 756-756	2.2	
19	Pretreatment Cytogenetic Abnormalities Are Predictive of Induction Success, Cumulative Incidence of Relapse and Overall Survival in Patients \geq 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 3293-3293	2.2	
18	Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2005 , 106, 1138-1138	2.2	
17	Gene Expression Profiling Identifies Distinct Subclasses in Core Binding Factor Acute Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 673-673	2.2	
16	Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.. <i>Blood</i> , 2005 , 106, 2352-2352	2.2	
15	Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. <i>Haematologica</i> , 2005 , 90, 194-9	6.6	13
14	The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. <i>Haematologica</i> , 2005 , 90, 1626-34	6.6	31
13	CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. <i>British Journal of Haematology</i> , 2004 , 126, 527-35	4.5	25
12	Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2004 , 350, 1605-16	59.2	822

11	MLL/AF9 Fusion Transcript Quantification in t(9;11)-Positive AML Identify Patients with High Risk of Relapse.. <i>Blood</i> , 2004 , 104, 3015-3015	2.2	
10	Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling.. <i>Blood</i> , 2004 , 104, 2037-2037	2.2	
9	Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.. <i>Blood</i> , 2004 , 104, 2896-2896	2.2	
8	Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2003 , 38, 274-80	5	23
7	Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2480-5	2.2	87
6	Pathogenic complexity of gastric B-cell lymphoma. <i>Blood</i> , 2002 , 100, 1095-6; author reply 1096-7	2.2	5
5	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. <i>Blood</i> , 2002 , 100, 4372-80	2.2	690
4	Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3254-61	2.2	258
3	Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. <i>International Journal of Cancer</i> , 2001 , 93, 80-4	7.5	30
2	Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. <i>Genes Chromosomes and Cancer</i> , 2001 , 31, 316-25	5	73
1	Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. <i>British Journal of Haematology</i> , 1999 , 104, 382-91	4.5	36